Voveran sr
Voveran sr Price range: $ 41,00 through $ 61,00
Back to products
Wellbutrin
Wellbutrin Price range: $ 66,00 through $ 627,00

Waklert

Price range: $ 65,00 through $ 426,00

Waklert is a highly effective medication designed to promote wakefulness and improve alertness in adults experiencing excessive daytime sleepiness. It is specifically indicated for the management of conditions such as narcolepsy and obstructive sleep apnea. Additionally, this medication helps individuals struggling with shift work disorder to maintain a steady state of vigilance during their working hours. The active ingredient, Armodafinil, is known for its ability to provide long-lasting focus and cognitive clarity throughout the day. By targeting specific centers in the brain, Waklert helps users overcome the debilitating effects of sleep-related exhaustion.

Active substance: Armodafinil
SKU: Waklert Categories: ,
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Waklert contains armodafinil, which belongs to a class of central nervous system agents known as wakefulness-promoting medications. In the United States, armodafinil is regulated as a prescription medication and a Schedule IV controlled substance due to its potential for misuse and dependence. It is primarily prescribed to increase wakefulness in adult patients experiencing excessive sleepiness associated with specific sleep disorders.

Because armodafinil affects neurotransmitter systems in the brain, proper medical evaluation is required prior to initiating therapy. Healthcare providers determine appropriate utilization based on an individual’s diagnostic evaluation, cardiovascular health, and medical history.

Property Details
Active ingredient Armodafinil
Therapeutic class Wakefulness-promoting agent
Dosage form Oral tablet
Route of administration Oral
Primary purpose Management of excessive daytime sleepiness
Prescription status Prescription (Rx) / Schedule IV Controlled Substance

How the drug works

Armodafinil is the R-enantiomer of racemic modafinil. Pharmacologically, armodafinil acts primarily as a dopamine reuptake inhibitor, binding to the dopamine transporter (DAT) and blocking dopamine reuptake. This leads to increased extracellular concentrations of dopamine in specific brain regions, including the hypothalamus and striatum. Beyond dopamine, armodafinil indirectly influences other neurotransmitter systems, increasing extracellular levels of norepinephrine, histamine, and glutamate, while reducing levels of gamma-aminobutyric acid (GABA). Unlike traditional sympathomimetic stimulants such as amphetamines or methylphenidate, armodafinil demonstrates a lower propensity for widespread central nervous system stimulation, resulting in wakefulness promotion with distinct pharmacological characteristics.

Main uses

The U.S. Food and Drug Administration (FDA) has approved armodafinil to improve wakefulness in adult patients diagnosed with excessive daytime sleepiness associated with three specific clinical conditions: obstructive sleep apnea (OSA), narcolepsy, and shift work disorder (SWD). In patients with OSA, armodafinil is indicated as an adjunct to continuous positive airway pressure (CPAP) therapy or other primary treatments; it does not treat the underlying airway obstruction. Any use of armodafinil outside these FDA-approved indications–such as for general fatigue, cognitive enhancement, or mood disorders–is considered off-label use. Off-label prescribing must be carefully evaluated by a licensed healthcare provider based on patient-specific risk-benefit considerations.

Dosing schedule

Dosage regimens for armodafinil are determined individually based on the specific clinical indication and patient response. For narcolepsy and obstructive sleep apnea, the standard recommended adult dosage is 150 mg or 250 mg administered once daily as a single dose in the morning. For shift work disorder, the typical recommended dosage is 150 mg taken approximately one hour prior to the start of the work shift. Tablets should be swallowed whole with water and may be taken with or without food. In patients with severe hepatic impairment, the dosage must be reduced, usually to 50 mg or 100 mg daily, as drug clearance is significantly decreased in the presence of severe liver dysfunction.

What happens in the body

Armodafinil exhibits linear, time-independent kinetics following single and multiple oral doses. Peak plasma concentrations (Cmax) are reached approximately two hours after oral administration under fasted conditions, though food intake may delay peak concentration by approximately two to four hours without significantly altering overall systemic exposure. Armodafinil has an elimination half-life of approximately 12 to 15 hours, which supports once-daily dosing. The drug is extensively metabolized in the liver via hydrolytic pathways and cytochrome P450 enzymatic pathways, predominantly CYP3A4/5, yielding inactive metabolites that are excreted mainly by the kidneys. Renal elimination of intact armodafinil is negligible, accounting for less than 1% of the administered dose.

Compatibility with other medicines

Armodafinil possesses complex metabolic pathways that create potential for multiple clinically significant drug-drug interactions. It serves as a moderate inducer of the CYP3A4 enzyme, which means it can decrease the plasma concentrations and therapeutic efficacy of co-administered drugs metabolized by CYP3A4. Crucially, this includes hormonal contraceptives; patients using hormonal birth control must utilize alternative or back-up non-hormonal barrier methods during treatment and for one month following discontinuation of armodafinil. Additionally, armodafinil inhibits CYP2C19, potentially increasing blood levels of medications cleared by this pathway, such as omeprazole, diazepam, and certain anticonvulsants or antidepressants.

Adverse reactions

Clinical studies indicate that armodafinil is generally tolerated, but adverse effects can occur. The most frequently reported adverse reaction is headache, occurring in roughly 15% to 20% of patients. Other common side effects include nausea, dizziness, insomnia, dry mouth, anxiety, and dyspepsia. Most mild side effects resolve as the body adjusts to the medication. However, serious dermatological reactions, including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have been reported with armodafinil. Although rare, these severe skin reactions can be life-threatening and require immediate discontinuation of the drug at the first sign of a rash, mucosal lesions, or systemic hypersensitivity.

Important precautions

Armodafinil requires careful medical oversight in several patient populations. Individuals with a history of cardiovascular disease, such as recent myocardial infarction, unstable angina, or severe hypertension, should be closely monitored, as armodafinil can cause modest elevations in blood pressure and heart rate. Psychiatric adverse events, including mania, hallucinations, aggression, and suicidal ideation, have occurred in patients taking wakefulness-promoting agents; caution is advised when prescribing to individuals with a history of psychosis or depression. In pediatric populations, safety and effectiveness have not been established. During pregnancy, armodafinil should be used only if the potential benefit justifies the potential risk to the fetus.

What to avoid while taking it

Armodafinil may be taken with or without food. Consuming high-fat meals prior to administration does not reduce the overall extent of drug absorption, but it can delay the onset of action by two to four hours, which may affect daytime alertness management. The co-ingestion of alcohol and armodafinil is not recommended. Alcohol affects the central nervous system in ways that counteract the wakefulness-promoting properties of armodafinil, and combined use may increase the risk of unpredictable central nervous system side effects, including impaired judgment, dizziness, and altered motor coordination.

First days of treatment

When beginning armodafinil therapy, patients usually notice an initial increase in daytime wakefulness within two to three hours after the first dose. During the initial days of treatment, mild transient effects such as a mild headache, heightened alertness, or light gastrointestinal discomfort may occur. It is critical to take the medication at the recommended time–typically early morning for narcolepsy or sleep apnea–to prevent disruption of nighttime sleep patterns. Patients should observe their response to the medication and avoid operating machinery or driving until they understand how armodafinil affects their cognitive and motor function.

If you skip a dose

If a patient misses a daily dose of armodafinil, it should be taken as soon as remembered, provided it is still early in the day. However, if the missed dose is remembered late in the afternoon or evening, it should be skipped entirely, and the normal dosing schedule resumed the following morning. Taking armodafinil late in the day can lead to prolonged wakefulness and severe nighttime insomnia. Patients should never double the dose or take extra tablets to compensate for a missed dose, as this increases the risk of cardiovascular and central nervous system adverse events.

Storage and expiration

Armodafinil tablets should be stored at controlled room temperature, ideally between 68°F and 77°F (20°C to 25°C), with permitted excursions between 59°F and 86°F (15°C to 30°C). Keep the medication in its original packaging, tightly closed, and protected from excessive moisture, heat, and direct light. Do not store tablets in humid environments such as bathroom cabinets. Keep armodafinil out of reach of children and pets. Properly discard any medication that has expired or is no longer needed in accordance with local drug take-back programs or community disposal guidelines.

Q&A

Does armodafinil cure underlying sleep disorders like obstructive sleep apnea?

No, armodafinil does not cure underlying sleep disorders, nor does it replace primary mechanical treatments like CPAP therapy for obstructive sleep apnea. It is designed solely as an adjunctive symptomatic treatment to help reduce excessive daytime sleepiness while the underlying condition is medically managed.

Can armodafinil interfere with hormonal birth control methods?

Yes, armodafinil induces CYP3A4 hepatic enzymes, which accelerates the breakdown of synthetic estrogen and progestin hormones. Patients taking hormonal contraceptives must use an alternative non-hormonal birth control method, such as condoms or an IUD, during treatment and for one month after stopping armodafinil.

What should be done if a skin rash develops after taking armodafinil?

If a skin rash, hives, blistering, or mucosal peeling occurs, stop taking armodafinil immediately and seek emergency medical care. Although uncommon, serious and potentially life-threatening skin reactions such as Stevens-Johnson syndrome have been reported with this drug class.

How does armodafinil differ from conventional wakefulness stimulants?

Armodafinil promotes wakefulness primarily by inhibiting dopamine reuptake, whereas traditional stimulants often cause massive direct release of monoamines. Consequently, armodafinil generally presents a distinct physiological response and lower potential for central nervous system overstimulation compared to classic amphetamine-based stimulants.

Is it safe to drive after taking armodafinil?

Although armodafinil is prescribed to increase wakefulness, it may not completely restore normal alertness in all individuals. Patients should avoid driving or operating heavy machinery until they have evaluated their personal degree of wakefulness and cognitive response to the drug.

In accordance with FDA requirements.

This text is for informational purposes only and does not constitute individual medical advice.

Additional information
Dosage

150 mg

Package

30 pills

,

60 pills

,

100 pills

,

200 pills

,

300 pills

,

500 pills

Ενεργός Ουσία